Cystic Fibrosis trials in the Netherlands: Trial Insights

Filters: Condition: Cystic Fibrosis Country / region: Netherlands Clear all

76 trials match Source: ClinicalTrials.gov registrations

Top lead sponsors
Category	Trials
Vertex Pharmaceuticals Incorporated	30
Maastricht University Medical Center	6
Boehringer Ingelheim	4
PTC Therapeutics	4
Erasmus Medical Center	3
Gilead Sciences	3
Lakefront Biotherapeutics NV	3
AbbVie	2
Insmed Incorporated	2
Novartis Pharmaceuticals	2

Top conditions
Category	Trials
Cystic Fibrosis	76
Lung Diseases	4
Asthma	3
Genetic Diseases, Inborn	3
Pseudomonas Infections	3
Inflammation	2
Pancreatic Diseases	2
Pneumonia	2
Respiratory Tract Diseases	2
Respiratory Tract Infections	2

Trials

Showing 26 to 50 of 76. Each trial links to its page on Pharma Observatory.

DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis NCT03485456Phase 1/2Unknown statusUniversity Medical Center GroningenStarted 2019
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis NCT03912233Phase 2CompletedVertex Pharmaceuticals IncorporatedStarted 2019
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis NCT03911713Phase 2CompletedVertex Pharmaceuticals IncorporatedStarted 2019
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT03525574Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2018
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) NCT03525548Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2018
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) NCT03525444Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2018
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. NCT03540524Phase 1CompletedLakefront Biotherapeutics NVStarted 2018
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis NCT03768089Phase 1/2CompletedVertex Pharmaceuticals IncorporatedStarted 2018
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis NCT03451045Phase 2CompletedCorbus Pharmaceuticals Inc.Started 2017
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria NCT03219164Phase 3TerminatedGilead SciencesStarted 2017
The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation NCT03285100ObservationalUnknown statusCanisius-Wilhelmina HospitalStarted 2017
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis NCT03119649Phase 2CompletedLakefront Biotherapeutics NVStarted 2017
Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation NCT03061331Phase 2CompletedVertex Pharmaceuticals IncorporatedStarted 2017
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis NCT03227471Phase 1/2CompletedVertex Pharmaceuticals IncorporatedStarted 2017
Breath Analysis in Children by New Point-of-care Instruments NCT03377686ObservationalCompletedMaastricht University Medical CenterStarted 2016
Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) NCT02690519Phase 2CompletedLakefront Biotherapeutics NVStarted 2016
Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis NCT02456103Phase 3TerminatedPTC TherapeuticsStarted 2015
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation NCT02565914Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2015
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) NCT02445053ObservationalCompletedVertex Pharmaceuticals IncorporatedStarted 2015
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation NCT02392234Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2015
Saline Hypertonic in Preschoolers + CT NCT02950883Phase 2/3CompletedUniversity of Washington, the Collaborative Health Studies Coordinating CenterStarted 2015
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor NCT02347657Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2015
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients NCT02170025Phase 2TerminatedBayerStarted 2014
Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study NCT02907788ObservationalCompletedErasmus Medical CenterStarted 2014
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) NCT02139306Phase 3CompletedPTC TherapeuticsStarted 2014

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age NCT05882357Enrollment change70 to 67October 17, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory